FY2025 Financial Results

The presentation was conducted in Japanese with simultaneous interpretation.
Please note that the accuracy of the interpretation cannot be fully guaranteed.

from the beginning

FY2025 Financial Results

Cautionary Statement Regarding Forward-Looking Information

FY2025 Results

FY2025 Overview

• FY2025 Financial Results

• FY2025 Financial Results: Main Brands

• FY2025 Financial Results: Cost Items

• Lifecycle Management of Strategic Brands: FY2025 Achievements

• enfortumab vedotin (EV) / PADCEV: Latest Status

• Progress in Focus Area Approach: FY2025 Achievements

• Progress in Focus Area Approach: New Clinical Programs

FY2026 Outlook

FY2026 Outlook: Overview

• FY2026 Forecast

• FY2026 Forecast: Main Brands

• Lifecycle Management of Strategic Brands: FY2026 Key Expected Events

• Progress in Pipeline: FY2026 Key Expected Events

Review of Corporate Strategic Plan 2021

• Transformation of Organizational Culture and Operating Model

• Review of Performance Goals in Corporate Strategic Plan 2021

• Three Enterprise Priorities

• Growth Strategy: Maximize Potential of Strategic Brands

• Bold Ambition: Increase Pipeline Value

• Sustainable Margin Transformation:Company-wide Cost Optimization

• Revenue and Core OP Growth over CSP2021 Period

• Key Takeaways

• Upcoming Event

Appendix

• Strategic Brands: Potential Peak Sales (as of Apr 2026)

• Capital Allocation

• FY2025 Actual: FX Rate

• FY2026 Forecast: FX Rate & FX Sensitivity

• Balance Sheet & Cash Flow Highlights

• Balance of Bonds and Borrowings Highlights

• Main Intangible Assets (as of Mar 31, 2026)

• Sustainable Margin Transformation

• Nonclinical data for New Programs

• Robust Pipeline of Astellas

• Progress in Overall Pipeline

• enfortumab vedotin (EV) (1/4): Nectin-4 Targeted ADCNumber of Eligible Patients

• enfortumab vedotin (EV) (2/4): Clinical Studies

• enfortumab vedotin (EV) (3/4): Study Data by Disease Stage

• enfortumab vedotin (EV) (4/4): Development for Muscle-Invasive Bladder Cancer (MIBC)

• zolbetuximab: anti-Claudin 18.2 Monoclonal Antibody

• fezolinetant: NK3 Receptor Antagonist

• gilteritinib: FLT3 Inhibitor

• Progress in setidegrasib

• Pipeline of Primary Focus Targeted Protein Degradation

• Progress in ASP2138

• Portfolio of Claudin 18.2-Targeted Therapies

• Progress in ASP7317

• Progress in AT845

• VIR-5500

Q&A

• Q&A1

• Q&A2

• Q&A3

• Q&A4

• Q&A5

• Q&A6

• Q&A7

• Q&A8

• Q&A9